$0.02
0.005[33.33%]
At close: Apr 24
Sorrento Therapeutics
(OTCEM:SRNE)Sorrento Therapeutics Stock (OTC:SRNE), Analyst Ratings, Price Targets, Predictions
Sorrento Therapeutics Inc has a consensus price target of $12.5, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, HC Wainwright & Co., and HC Wainwright & Co. on November 2, 2022, March 25, 2022, and August 9, 2021. With an average price target of $17 between Cantor Fitzgerald, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 84900.00% upside for Sorrento Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sorrento Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/02/2022 | SRNE | Buy Now | Sorrento Therapeutics | $0.02 | 24900% | Cantor Fitzgerald | Brandon Folkes | → $5 | Initiates | → Overweight | Get Alert |
| 03/25/2022 | SRNE | Buy Now | Sorrento Therapeutics | $0.02 | 99900% | HC Wainwright & Co. | Raghuram Selvaraju | $26 → $20 | Maintains | Buy | Get Alert |
| 08/09/2021 | SRNE | Buy Now | Sorrento Therapeutics | $0.02 | 129900% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Sorrento Therapeutics (SRNE)?
The latest price target for Sorrento Therapeutics (OTCEM: SRNE) was reported by Cantor Fitzgerald on November 2, 2022. The analyst firm set a price target for $5.00 expecting SRNE to rise to within 12 months (a possible 24900.00% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sorrento Therapeutics (SRNE)?
The latest analyst rating for Sorrento Therapeutics (OTCEM: SRNE) was provided by Cantor Fitzgerald, and Sorrento Therapeutics initiated their overweight rating.
When was the last upgrade for Sorrento Therapeutics (SRNE)?
There is no last upgrade for Sorrento Therapeutics.
When was the last downgrade for Sorrento Therapeutics (SRNE)?
There is no last downgrade for Sorrento Therapeutics.
When is the next analyst rating going to be posted or updated for Sorrento Therapeutics (SRNE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sorrento Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sorrento Therapeutics was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
Is the Analyst Rating Sorrento Therapeutics (SRNE) correct?
While ratings are subjective and will change, the latest Sorrento Therapeutics (SRNE) rating was a initiated with a price target of $0.00 to $5.00. The current price Sorrento Therapeutics (SRNE) is trading at is $0.02, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.